Novel targets for myeloma bone disease

Research output: Contribution to journalReview article

21 Scopus citations

Abstract

Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80% of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients.

Original languageEnglish (US)
Pages (from-to)1377-1387
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2008

    Fingerprint

Keywords

  • Bone disease
  • Myeloma
  • Novel treatments
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this